SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (18)4/12/1999 11:31:00 PM
From: scaram(o)uche  Read Replies (2) | Respond to of 226
 
MZ:

You might ask in the VION or TCLN threads?

Rick



To: Miljenko Zuanic who wrote (18)4/13/1999 8:32:00 PM
From: SnowShredder  Read Replies (1) | Respond to of 226
 
Hi Miljenko, Thanx for the great find...it kind of reminds me of a more complex version of a viral vector (gene therapy) that contains a herpes TK gene...after infections, the patient is administered gancyclovir and the infected cells, that express the TK gene, die as well as some of the neighboring cells. The specifity of infecting a target cell probably isn't as good as a mAb, but it is improving. Best of Luck, Where'd He Go?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News